Literature DB >> 32963115

Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection.

Sang Hyun Ra1, Joon Seo Lim2, Gwang-Un Kim3, Min Jae Kim1, Jiwon Jung1, Sung-Han Kim4.   

Abstract

BACKGROUND: Asymptomatic individuals with n class="Disease">SARS-CoV-2 infection have viable viral loads and have been linked to several transmission cases. However, data on the viral loads in such individuals are lacking. We assessed the viral loads in asymptomatic individuals with SARS-CoV-2 infection in comparison with those in symptomatic patients with COVID-19.
METHODS: Study participants were recruited from a community facility designated for the isolation of patients with mild COVID-19 in South Korea. The presence of symptoms was evaluated with a questionnaire-based survey. Viral loads in the upper respiratory tract were measured with real-time reverse transcription-PCR (RT-PCR) targeting the E, RdRp and N genes of SARS-CoV-2, with a cycle threshold (Ct) value of 40 for determining positivity.
RESULTS: In 213 patients with SARS-CoV-2 infection, 41 (19%) had remained asymptomatic from potential exposure to laboratory confirmation and admission; of them, 39 (95%) underwent follow-up RT-PCR testing after a median 13 days. In 172 symptomatic patients, 144 (84%) underwent follow-up RT-PCR testing. Twenty-one (54%) asymptomatic individuals and 92 (64%) symptomatic patients tested positive for SARS-CoV-2 at follow-up. Asymptomatic individuals and symptomatic patients did not show any significant differences in the mean Ct values of the E (31.15 vs 31.43; p>0.99), RdRp (32.26 vs 32.93; p=0.92) and N (33.05 vs 33.28; p>0.99) genes.
CONCLUSION: Approximately one-fifth of the individuals without severe symptoms were asymptomatic, and their viral loads were comparable to those in symptomatic patients. A large proportion of mildly symptomatic patients with COVID-19 or asymptomatic individuals with SARS-CoV-2 showed persistent positive upper respiratory RT-PCR results at follow-up. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  viral infection

Mesh:

Year:  2020        PMID: 32963115      PMCID: PMC7462047          DOI: 10.1136/thoraxjnl-2020-215042

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


Do asymptomatic individuals with SARS-CoV-2 infection have the potential to sigene">nificaene">ntly coene">ntribute to the commuene">nity spread of n class="Disease">COVID-19? In a series of 213 patients with n class="Disease">COVID-19 without severe symptoms, 19% were asymptomatic from potential exposure to laboratory confirmation and admission. Asymptomatic individuals had comparable loads of SARS-CoV-2 genes to symptomatic patients. Asymptomatic individuals were frequent among those infected with n class="Species">SARS-CoV-2, but harboured a comparable viral load compared with that of symptomatic patients and may thus act as a meaningful driving force for the community spread of COVID-19.

Introduction

The presence of asymptomatic individuals with positive reverse transcription-PCR (RT-PCR) results for SARS-CoV-2 has been noted even in the early reports of the n class="Disease">COVID-19 outbreak.1 2 Moreover, several case reports have suggested that the transmission of SARS-CoV-2 from asymptomatic individuals is possible.1–3 However, owing to the rapid spread of COVID-19 and the resulting shortage in PCR testing capabilities, asymptomatic individuals with SARS-CoV-2 infection are likely to go unnoticed by healthcare workers. Therefore, asymptomatic individuals have not been systematically evaluated in terms of their viral load and infectivity, and thus, the extent of their possible contribution to the community spread of COVID-19 is unknown. In South Korea, a large cluster of COVID-19 cases was identified in Daegu City; this cluster was soon revealed to be related to a single religious group.4 Thereafter, Koreaene">n epidemiologic teams thoroughly traced the close contacts of this religious group aene">nd discovered more thaene">n 3000 cases of n class="Disease">COVID-19 with a wide range of symptom severity, from none to severe. Those without severe symptoms were admitted to dedicated care facilities for isolation and monitoring. As a result of this unique situation, we were able to assess many asymptomatic individuals who were otherwise unlikely to be identified as cases of COVID-19. Here, we assessed the viral load in the upper respiratory tract of asymptomatic individuals infected with n class="Species">SARS-CoV-2 using the cycle threshold (Ct) values of RT-PCR targeting SARS-CoV-2 genes and compared the results with those from patients with mild symptoms of COVID-19.

Methods

Study participants

We recruited study participants from a commuene">nity care facility designated for n class="Species">patients with COVID-19 without severe symptoms. The admission criteria were as follows: COVID-19 national early warning score <4; without high-risk profiles such as age ≥65 years, chronic illness, current smoker and those requiring supplemental oxygen due to low oxygen saturation <90%. This facility is located approximately 50 miles from Daegu City and housed a total of 260 patients at the time of this study. In March 2020, we conducted a survey on the patients to gather information on aene">ny n class="Disease">COVID-19 symptom as well as age, sex and underlying disease. Asymptomatic individuals were defined as those who did not report any of the following symptoms: fever (>37.5°C), chills, myalgia, fatigue, rhinorrhea, nasal congestion, hyposmia, hypogeusia, sore throat, dyspnoea, cough, sputum production, haemoptysis, headache, dizziness, anorexia, nausea, vomiting, abdominal pain and diarrhoea. Patients participated in this study by filling out the survey, and written informed consent was obtained from each patient. Missing data were obtained with telephone interviews by trained physicians. This study was approved by the institutional review board of Asan Medical Center.

Sample acquisition

All sample acquisitions for follow-up RT-PCR at the care centre were carried out by experienced physicians donning the complete personal protective equipment. According to the Center for Disease Control guidelines5 for obtaining clinical specimens for confirming COVID-19, we obtained swab samples from both the nasopharyene">nx aene">nd oropharyene">nx aene">nd combined them in a single tube to maximise the sensitivity of the RT-PCR test aene">nd minimise the use of resources. The nasopharyene">ngeal samples were obtained according to a previously reported method,6 in which swabs were inserted through the nostril to a distaene">nce equivalent to the outer opening of the ear caene">nal aene">nd gently rubbed for several seconds to absorb the secretions. For oropharyene">ngeal samples, the n class="Disease">tonsillar pillars were swabbed. The nasopharynx and oropharynx were swabbed once each with separate swabs, placed in a single tube containing 300 µL of viral transport medium and transported to a reference laboratory under cold conditions for subsequent RNA extraction and RT-PCR testing.

RT-PCR for SARS-CoV-2 genes

Viral RNA from the upper respiratory tract swab samples was extracted using the MagNA Pure 96 System (Roche Diagnostics, Mannheim, Germany), according to the manufacturer’s instructions. The resulting samples were tested for the E, RdRp aene">nd N genes of n class="Species">SARS-CoV-2 with real-time RT-PCR using theAllplex 2019-nCoV Assay kit (Seegene)7 with CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, California, USA) under the following condition: 20 min at 50°C for reverse transcription and 15 min at 95°C for denaturation as the initial step, followed by 45 cycles of 15 s each at 94°C and 30 s at 58°C. A Ct value of <40 was used as the cut-off for determining positivity, according to the manufacturer’s instructions.

Statistical analysis

Categorical variables were compared using the Fisher’s exact test or χ2 test as appropriate, and continuous variables were compared using the Mann-Whitney U test or Student’s t-test as appropriate. All tests of significance were two-tailed, and p values <0.05 were considered statistically significant. Continuous variables are represented as median values with IQR for non-normally distributed variables and as mean±SD values for normally distributed variables. All statistical analyses were carried out in IBM SPSS Statistics for Windows, V.23.0 (IBM Corp., Armonk, New York, USA).

Results

Of the 260 patients with n class="Disease">COVID-19, 213 (82%) participated in this study. During the observation period, 41 (19%; 95% CI 15% to 25%) individuals remained asymptomatic, of whom 39 (95%) underwent follow-up RT-PCR testing at the care facility. Of the 172 (81%; 95% CI 75% to 86%) patients with mild symptoms of COVID-19, 144 (94%) underwent follow-up RT-PCR testing. Thus, a total of 183 patients (asymptomatic, n=39; symptomatic, n=144) with follow-up RT-PCR results were included in the analysis. The baseline clinical characteristics of asymptomatic individuals and symptomatic patients are shown in table 1. On follow-up RT-PCR testing, 21 (54%) asymptomatic individuals aene">nd 92 (64%) symptomatic n class="Species">patients tested positive for SARS-CoV-2 genes (p=0.25). The mean Ct values of the SARS-CoV-2 genes in asymptomatic individuals and symptomatic patients were as follows: E gene, 31.15 versus 31.43 (p>0.99); RdRp gene, 32.26 versus 32.93 (p=0.92) and N gene, 33.05 versus 33.28 (p>0.99) (table 1).
Table 1

Characteristics of asymptomatic individuals with SARS-CoV-2 infection and symptomatic patients with COVID-19*

Asymptomatic individuals (n=39)Symptomatic patients (n=144)P value
Age, median (IQR), y25.0 (21.5–34.0)26.5 (22.0–46.0)0.22
Male sex, n (%)22 (56)62 (43)0.14
Underlying diseases, n (%)3 (8)26 (18)0.12
 Hypertension05
 Asthma04
 Liver disease02
 COPD01
 Solid cancer01
 Rheumatologic disease10
 Other2†13‡
Interval from the first swab for diagnosis to the start of isolation, median (IQR), days6.0 (4.5–7.0)6.0 (4.0–9.0)0.84
Interval from initial confirmation to follow-up RT-PCR testing, median (IQR), days12 (9–14)13 (11–15)0.06
Interval from symptom onset to follow-up RT-PCR testing, median (IQR), daysNA26±6NA
Positive result on follow-up RT-PCR testing, n (%)21 (54)92 (64)0.25
Ct values, mean±SD
E gene31.15±2.7231.43±2.80>0.99
RdRp gene32.26±2.8632.93±2.870.92
N gene33.05±2.5233.28±2.48>0.99

*Categorical variables were compared using the Fisher’s exact test or χ2 test, as appropriate, and continuous variables were compared using the Mann-Whitney U test or Student’s t-test. All tests of significance were two-tailed.

†Includes thyroid disease (n=1) and allergic rhinitis (n=1).

‡Includes allergic rhinitis (n=8), hyperlipidaemia (n=2), thyroid disease (n=2) and nephrotic syndrome (n=1).

Ct, cycle threshold; NA, not available; RT-PCR, reverse transcription-PCR.

Characteristics of asymptomatic individuals with SARS-CoV-2 infection aene">nd symptomatic n class="Species">patients with COVID-19* *Categorical variables were compared using the Fisher’s exact test or χ2 test, as appropriate, and continuous variables were compared using the Mann-Whitney U test or Student’s t-test. All tests of significance were two-tailed. †Includes thyroid disease (n=1) and n class="Disease">allergic rhinitis (n=1). ‡Includes allergic rhinitis (n=8), hyperlipidaemia (n=2), n class="Disease">thyroid disease (n=2) and nephrotic syndrome (n=1). Ct, cycle threshold; NA, not available; RT-PCR, reverse transcription-PCR.

Discussion

A recent study on 72 314 Chinese patients reported that the proportion of asymptomatic individuals with n class="Species">SARS-CoV-2 was approximately 1%.8 However, this study was based on patients from the Hubei Province, where the sudden shortage of healthcare resources is presumed to have led to a selection bias towards the exclusion of asymptomatic individuals and patients with mild symptoms. Therefore, the actual prevalence of asymptomatic cases of COVID-19 is most likely higher than 1%. Accordingly, we found that 19% of patients with COVID-19 had remained asymptomatic from potential exposure to laboratory confirmation and facility admission. In our study, 54% of asymptomatic individuals and 64% of patients with mild symptoms showed positive results in the follow-up PCR testing conducted at a mediaene">n of 13 days from diagnosis. Similarly, Xiao et al reported that in 301 n class="Species">patients with mild-to-moderate symptoms of COVID-19, the median duration from symptom onset to an effective negative SARS-CoV-2 result was 20 days.9 A recent Chinese study also reported that the median duration of viral shedding assessed by SARS-CoV-2 RT-PCR was 21 days in patients with mild COVID-19.10 These results suggest that patients with COVID-19 may experience a more protracted course than that initially hypothesised. However, our results should be interpreted with caution because positive RT-PCR results do not necessarily indicate the presence of viable virus, for which cell culture is needed for confirmation. Indeed, recent studies have shown that viable virus was isolated within 10 days from the symptom onset.11 12 Therefore, further studies are needed to determine whether the prolonged duration of positive RT-PCR results in asymptomatic individuals with SARS-CoV-2 infection or mildly symptomatic patients with COVID-19 can be translated into a continuous need for precaution and quarantine. Previous studies have shown that viable SARS-CoV-2 was isolated from asymptomatic individuals aene">nd that a certain number of cases are likely to have been traene">nsmitted from asymptomatic individuals.12–15 Indeed, we fouene">nd that asymptomatic individuals had RT-PCR Ct values for n class="Species">SARS-CoV-2 genes comparable with those of patients with mild symptoms of COVID-19. Considering that most asymptomatic individuals with COVID-19 are likely to go unnoticed by healthcare workers and continue to reside within communities, such individuals may act as an essential driving force for the community spread of COVID-19 and the ongoing pandemic state. Our data thus support the general public use of face masks as well as broadening the scope of SARS-CoV-2 testing to include asymptomatic persons in certain high-risk settings until such time as further data become available regarding the duration and transmissibility of viable virus shedding from asymptomatic individuals with SARS-CoV-2 infection to support these recommendations. This study is limited in that the study population largely comprised those in their 20s and 30s, a characteristic that is likely linked to the demographic of the Shincheonji religious group. Therefore, the prevalence of asymptomatic individuals and their viral load may be different in other age groups. Moreover, there is a possibility of recall bias concerning the self-reports of symptoms; nevertheless, as the study participants were highly cooperative aene">nd well educated on the gravity of the current paene">ndemic, we believe that such bias is not likely to have significaene">ntly affected our main results. Additionally, we could not obtain the results of the initial RT-PCR tests of the n class="Species">patients because each of them underwent RT-PCR tests at separate triages. Finally, the duration from the initial confirmation to follow-up RT-PCR testing for symptomatic patients was slightly longer than that for asymptomatic individuals; such a discrepancy occurred because the guideline of the community care facility recommended conducting follow-up RT-PCRs for patients after symptom resolution and at least 7 days after diagnosis. However, this bias is not likely to have substantially affected our main findings on the Ct values in the follow-up RT-PCR testing. In conclusion, we report that as many as one-fifth of individuals with SARS-CoV-2 infection without severe symptoms were asymptomatic aene">nd the viral load in their nasopharyene">nx was comparable to that in n class="Species">patients with mild symptoms. In addition, a large proportion of mildly symptomatic patients or asymptomatic individuals showed persistent positive upper respiratory RT-PCR results at follow-up. Asymptomatic individuals with SARS-CoV-2 infection may contribute to the ongoing community spread of COVID-19, but further studies with cell culture are needed to evaluate the transmissibility of COVID-19 from asymptomatic individuals to inform a recommendation on universal personal protective equipment.
  14 in total

1.  How to Obtain a Nasopharyngeal Swab Specimen.

Authors:  Francisco M Marty; Kaiwen Chen; Kelly A Verrill
Journal:  N Engl J Med       Date:  2020-04-17       Impact factor: 91.245

2.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.

Authors:  Camilla Rothe; Mirjam Schunk; Peter Sothmann; Gisela Bretzel; Guenter Froeschl; Claudia Wallrauch; Thorbjörn Zimmer; Verena Thiel; Christian Janke; Wolfgang Guggemos; Michael Seilmaier; Christian Drosten; Patrick Vollmar; Katrin Zwirglmaier; Sabine Zange; Roman Wölfel; Michael Hoelscher
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

3.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.

Authors:  Lirong Zou; Feng Ruan; Mingxing Huang; Lijun Liang; Huitao Huang; Zhongsi Hong; Jianxiang Yu; Min Kang; Yingchao Song; Jinyu Xia; Qianfang Guo; Tie Song; Jianfeng He; Hui-Ling Yen; Malik Peiris; Jie Wu
Journal:  N Engl J Med       Date:  2020-02-19       Impact factor: 91.245

4.  Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study.

Authors:  Shufa Zheng; Jian Fan; Fei Yu; Baihuan Feng; Bin Lou; Qianda Zou; Guoliang Xie; Sha Lin; Ruonan Wang; Xianzhi Yang; Weizhen Chen; Qi Wang; Dan Zhang; Yanchao Liu; Renjie Gong; Zhaohui Ma; Siming Lu; Yanyan Xiao; Yaxi Gu; Jinming Zhang; Hangping Yao; Kaijin Xu; Xiaoyang Lu; Guoqing Wei; Jianying Zhou; Qiang Fang; Hongliu Cai; Yunqing Qiu; Jifang Sheng; Yu Chen; Tingbo Liang
Journal:  BMJ       Date:  2020-04-21

5.  Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study.

Authors:  Ai Tang Xiao; Yi Xin Tong; Chun Gao; Li Zhu; Yu Jie Zhang; Sheng Zhang
Journal:  J Clin Virol       Date:  2020-04-11       Impact factor: 3.168

6.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility.

Authors:  Melissa M Arons; Kelly M Hatfield; Sujan C Reddy; Anne Kimball; Allison James; Jesica R Jacobs; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Jonathan W Dyal; Josh Harney; Zeshan Chisty; Jeneita M Bell; Mark Methner; Prabasaj Paul; Christina M Carlson; Heather P McLaughlin; Natalie Thornburg; Suxiang Tong; Azaibi Tamin; Ying Tao; Anna Uehara; Jennifer Harcourt; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Patty Montgomery; Nimalie D Stone; Thomas A Clark; Margaret A Honein; Jeffrey S Duchin; John A Jernigan
Journal:  N Engl J Med       Date:  2020-04-24       Impact factor: 91.245

7.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.

Authors:  Sebastian Hoehl; Holger Rabenau; Annemarie Berger; Marhild Kortenbusch; Jindrich Cinatl; Denisa Bojkova; Pia Behrens; Boris Böddinghaus; Udo Götsch; Frank Naujoks; Peter Neumann; Joscha Schork; Petra Tiarks-Jungk; Antoni Walczok; Markus Eickmann; Maria J G T Vehreschild; Gerrit Kann; Timo Wolf; René Gottschalk; Sandra Ciesek
Journal:  N Engl J Med       Date:  2020-02-18       Impact factor: 91.245

8.  Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020.

Authors: 
Journal:  J Korean Med Sci       Date:  2020-03-16       Impact factor: 2.153

9.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

10.  The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis?

Authors:  Eric Farfour; Philippe Lesprit; Benoit Visseaux; Tiffany Pascreau; Emilie Jolly; Nadira Houhou; Laurence Mazaux; Marianne Asso-Bonnet; Marc Vasse
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-05-28       Impact factor: 3.267

View more
  49 in total

1.  Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients.

Authors:  Stefanie Lefever; Christophe Indevuyst; Lize Cuypers; Klaas Dewaele; Nicolas Yin; Frédéric Cotton; Elizaveta Padalko; Matthijs Oyaert; Julie Descy; Etienne Cavalier; Marc Van Ranst; Emmanuel André; Katrien Lagrou; Pieter Vermeersch
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

2.  Widespread outbreak of the COVID-19 virus during the second wave pandemic: the double face of absolute numbers.

Authors:  Marco Zuin; Gianluca Rigatelli; Giovanni Zuliani; Loris Roncon
Journal:  Pathog Glob Health       Date:  2021-01-11       Impact factor: 2.894

3.  Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities.

Authors:  Qing Yang; Tassa K Saldi; Patrick K Gonzales; Erika Lasda; Carolyn J Decker; Kimngan L Tat; Morgan R Fink; Cole R Hager; Jack C Davis; Christopher D Ozeroff; Denise Muhlrad; Stephen K Clark; Will T Fattor; Nicholas R Meyerson; Camille L Paige; Alison R Gilchrist; Arturo Barbachano-Guerrero; Emma R Worden-Sapper; Sharon S Wu; Gloria R Brisson; Matthew B McQueen; Robin D Dowell; Leslie Leinwand; Roy Parker; Sara L Sawyer
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

Review 4.  COVID-19 and Parkinson's disease: Defects in neurogenesis as the potential cause of olfactory system impairments and anosmia.

Authors:  Harini Sri Rethinavel; Sowbarnika Ravichandran; Risna Kanjirassery Radhakrishnan; Mahesh Kandasamy
Journal:  J Chem Neuroanat       Date:  2021-05-11       Impact factor: 3.052

5.  Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan.

Authors:  Xiaojuan Peng; Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

6.  Optimized protocol for a quantitative SARS-CoV-2 duplex RT-qPCR assay with internal human sample sufficiency control.

Authors:  Aileen G Rowan; Philippa May; Anjna Badhan; Carolina Herrera; Patricia Watber; Rebecca Penn; Michael A Crone; Marko Storch; Jeremy A Garson; Myra McClure; Paul S Freemont; Pinglawathee Madona; Paul Randell; Graham P Taylor
Journal:  J Virol Methods       Date:  2021-05-10       Impact factor: 2.014

Review 7.  A review of nasopharyngeal swab and saliva tests for SARS-CoV-2 infection: Disease timelines, relative sensitivities, and test optimization.

Authors:  Marylin Roque; Kevin Proudfoot; Vadim Mathys; Sophie Yu; Natalie Krieger; Thomas Gernon; Kash Gokli; Stanley Hamilton; Colin Cook; Yuman Fong
Journal:  J Surg Oncol       Date:  2021-06-06       Impact factor: 2.885

8.  Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.

Authors:  Shi-Wei Yin; Zheng Zhou; Jun-Ling Wang; Yun-Feng Deng; Hui Jing; Yi Qiu
Journal:  Virol J       Date:  2021-06-12       Impact factor: 4.099

9.  Ambient air pollution and low temperature associated with case fatality of COVID-19: A nationwide retrospective cohort study in China.

Authors:  Fei Tian; Xiaobo Liu; Qingchen Chao; Zhengmin Min Qian; Siqi Zhang; Li Qi; Yanlin Niu; Lauren D Arnold; Shiyu Zhang; Huan Li; Hualiang Lin; Qiyong Liu
Journal:  Innovation (Camb)       Date:  2021-06-18

Review 10.  Viral Load Difference between Symptomatic and Asymptomatic COVID-19 Patients: Systematic Review and Meta-Analysis.

Authors:  Marco Zuin; Valentina Gentili; Carlo Cervellati; Roberta Rizzo; Giovanni Zuliani
Journal:  Infect Dis Rep       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.